Abstract
Owing to the lack of an effective prevention and appropriate treatment, age-related macular degeneration (AMD) continues being the leading cause of central vision loss in patients older than 65 yr of age in the first world, and the third cause in developing countries. Despite a relatively low prevalence of choroideal neovascularization (CNV) in AMD, approximately a quarter of these patients will develop the complication (1,2). As expected, the prevalence is likely to increase as a consequence of increasing longevity.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Leibowitz HM, Krueger DE, Maunder LR, et al. The Framingham Eye Study Monograph: VI. Macular Degeneration. Surv Ophthalmol 1980;24(suppl):428–427.
Klein R, Klein BE, Linton KL. Prevalence of age-related maculopathy: the Beaver Dam Eye Study. Ophthalmology 1992;99:933–944.
Chaum E, Hatton MP. Gene Therapy for Genetic and Acquired Retinal Disease. Surv Opthalmol 2002;47:449–469.
Garcia Valenzuela E, Sharma SC. Rescue of retinal ganglion cells from axotomy-induced apoptosis through TRK oncogene transfer. Neuroreport 1998;9:165–170.
Lai CC, Wu WC, Chen SL, et al. Suppression of choroidal neovascularization by adenoassociated virus vector expressing angiostatin. Invest Ophthalmol Vis Sci 2001;42:2401–2407.
Semkova I, Kreppel F, Welsandt G, et al. Autologous transplantation of genetically modified iris pigment epithelial cells: A promising concept for the treatment of age-related macular degeneration and other disorders of the eye. Proc Natl Acad Sci USA 2002;99:13,090–13,095.
Tombran-Tink J, Johnson L. Neurontal differentiation of retinoblastoma cells induced by medium conditioned by human RPE cells. Invest Ophthalmol Vis Sci 1989;30:1700–1709.
Rasmussen HS, Rasmussen CS, Durham RG, et al. Looking into anti-angiogenic gene therapies for disorders of the eye. Drug Discov Today 2001;22:1171–1175.
Dawson DW, Volpert OV, Gillis P, et al. Pigment epithelium-derived factor: a potent inhibitor of angiogenesis. Science 1999;285:245–248.
Hyder SM, Stancel GM. Regulation of angiogenic growth factors in the female reproductive tract by estrogens and progestins. Mol Endocrinol 1999;13:806–811.
Ferrara N, Davis-Smyth T. The biology of vascular endothelial growth factor. EndocrRev 1997;18:4–25.
Klagsbrun M, D’Amore PA. Vascular endothelial growth factor and its receptors. Cytokine Growth Factor Rev 1996;7:259–270.
Rosen LS. Clinical Experience With Angiogenesis Signaling Inhibitors: Focuson Vascular Endothelial Growth Factor(VEGF) Blockers. Cancer Control 2002;9:36–44.
Jain RK. Tumor Angiogenesis and Accessibility: roleof Vascular Endothelial Growth Factor. Semin Oncol 2002;29:3–9.
Ambati J, Ambati BK, Yoo SH, etal. Age-related macular degeneration: etiology, pathogenesis, and the rapeutics trategies. Surv Ophthalmol 2003;48:257–293.
Witmer AN, Vrensen GF, Van Noorden CJ, etal. Vascular endothelial growth factors and angiogenesis in eye disease. Prog Retin Eye Res2003;22:1–29.
Ferrara N. Role of Vascular Endothelial Growth Factor in Physiologic and Pathologic Angiogenesis: Therapeutic Implications. SeminOncol 2002;29:10–14.
Sridhar SS, Shepherd FA. Targeting angiogenesis: are view of angiogenesis inhibitors in the treatment of lungcancer. LungCancer 2003;42:81–91.
Ray JM, Stetler-Stevenson WG. The role of matrix metalloproteases and their inhibitions in tumor invasion, metastasis and angiogenesis. Eur Respir J 1994;7:2062–2072.
Holz FG, Miller DW. Pharmacological therapy for age-related macular degeneration. Current developments and perspectives. Ophthalmologe 2003;100:97–103.
The Anecortave Acetate Clinical Study Group. Anecortave Acetateas Monotherapy for the Treatment of Subfoveal Lesions in Patients with Exudative Age-related Macular Degeneration (AMD). Interim (6months) Analysis of Clinical Safety and Efficacy. Retina 2003;23:14–23.
The Eyetech Study Group. Anti-vascular Endothelial Growth Factor Therapy for Subfoveal Choroidal Neovascularization Secondary to Age-related Macular Degneration. Phase II Study Results. Ophthalmology 2003;110:979–986.
Bhutto IA, Kim SY, McLeod DS, et al. Localization of collagen XVIII and the endostatin portion of collagen XVIII in aged human control eyes and eyes with age-related macular degeneration. Invest Ophthalmol Vis Sci 2004;45:1544–1552.
Pharmacological Therapy for Macular Degeneration Study Group. Interferon alfa-2a is ineffective for patients with choroidal neovascularization secondary to age-related macular degeneration. Results of a prospective randomized placebo-controlled clinical trial. Arch Ophthalmol 1997;115:865–872.
Ciardella AP, Donsoff IM, Guyer DR, et al. Antiangiogenesis agents. Opthalmol Clin North Am 2002;15:453–458.
Ciulla TA, Criswell MH, Danis RP, et al. Squalamine Lactate Reduces Choroidal Neovascularization in a Laser-injury Model in the Rat. Retina 2003;23:808–814.
Eyetech Study Group. Preclinical and phase 1A clinical evaluation of an anti-VEGF pegylated aptamer (EYE001) for the treatment of exudative age-related macular degeneration. Retina 2002;22:143–152.
Higgins RD, Sanders RJ, Tan Y, et al. Squalamine Improves Retinal Neovascularization. Invest Ophthalmol Vis Sci2000;41:1507–1512.
Nambu H, Nambu R, Melia M, Campochiaro PA. Combretastatin A-4 Phosphate Suppresses Development and Induces Regression of Choroidal Neovascularization. Invest Ophthalmol Vis Sci 2003;44:3650–3655.
Reich SJ, Fosnot J, Kuroki A, et al. Small interfering RNA (siRNA) targeting VEGF effectively inhibits ocular neovascularization in a mouse model. Mol Vis2003;9:210–216.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2007 Humana Press Inc., Totowa, NJ
About this chapter
Cite this chapter
Liggett, P.E., Lavaque, A.J. (2007). Macular Degeneration. In: Tombran-Tink, J., Barnstable, C.J. (eds) Retinal Degenerations. Ophthalmology Research. Humana Press. https://doi.org/10.1007/978-1-59745-186-4_4
Download citation
DOI: https://doi.org/10.1007/978-1-59745-186-4_4
Publisher Name: Humana Press
Print ISBN: 978-1-58829-620-7
Online ISBN: 978-1-59745-186-4
eBook Packages: MedicineMedicine (R0)